![Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy](https://oncodaily.com/pub/uploads/2023/12/download-17-1-e1718101670694.jpg)
Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy
Tanja Obradovic shared on LinkedIn:
“Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy are certain to be raised even more after announcement today that Phase 3 KeyVibe-010 study will be discontinued due to futility.
Study tested Vibostolimab and Pembrolizumab co-formulation as an adjuvant treatment in resected high-risk melanoma patients vs Pembrolizumab monotherapy standard of care.
Patients did not tolerate well co-formulated mix and higher discontinuation rate in the co-formulation arm prevented achievement of statistical significance for the primary endpoint of recurrence-free survival (RFS).
Numerous large Pharma and Biotech companies have invested heavily in TIGIT clinical pipeline but results so far have been mixed with major updates still pending.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023